Skip to content

A prospective, multi-center, non-randomized controlled study of laparoscopic and open cholecystectomy for advanced gallbladder cancer

A prospective, multi-center, non-randomized controlled study of laparoscopic and open cholecystectomy for advanced gallbladder cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119864
Enrollment
Unknown
Registered
2026-03-04
Start date
2024-03-18
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder carcinoma (GBC)

Interventions

Laparoscopic SURGERY Group:mini invasive Laparoscopic SURGERY

Sponsors

The second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Chinese citizens aged >=18 and <=75 years old; 2. Highly suspected or pathologically confirmed gallbladder cancer; 3. Acceptable radical surgery after multidisciplinary comprehensive evaluation; 4. Without preoperative anti-tumor chemoradiotherapy and biological targeted therapy; 5. The subjects understood and could cooperate with this study, and signed the informed consent; 6. On the basis of available evidence or investigator assessment, the patient would benefit from the therapeutic procedure.

Exclusion criteria

Exclusion criteria: 1. Concomitant diseases that, according to the investigator's judgment, seriously endanger the patient's safety or prevent the patient from completing the study; 2. The expected survival time is less than 3 months; 3. Unwilling to sign informed consent or unable to comply with the requirements of the study; 4. Patients with distant metastasis confirmed before or during operation: abdominal implantation, distant lymph node metastasis, liver or other organ metastasis, etc. Abdominal imaging data were used to evaluate patients with vascular invasion or intraoperative combined vascular resection. 5. The subjects received palliative surgery (R2) or other surgical methods; 6. According to the comprehensive judgment of the researcher, it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Complete cure resection rate;

Secondary

MeasureTime frame
intraoperative blood loss;Lymph node dissection status;Duration of the surgery;tumor marker;Postoperative complication rate;90-day unplanned readmission rate; ICU length of stay;Postoperative blood transfusion;Tme to ambulation; Time to resumption of oral intake;Time to drain removal;Surgical cost;;Hospitalization cost;Time to initiation of subsequent adjuvant therapy;Postoperative drainage volume and amylase level.;1-year survival rate;;5-year survival rate;Overall survival (OS);

Countries

China

Contacts

Public ContactDong Wei

The second Affiliated Hospital of Kunming Medical University

mdhiweidong@sina.com+86 871 6340 2881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026